Related references
Note: Only part of the references are listed.Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
Lambros Tselikas et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
Janelle C. Waite et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N. Gide et al.
CANCER CELL (2019)
A coiled-coil masking domain for selective activation of therapeutic antibodies
Vivian H. Trang et al.
NATURE BIOTECHNOLOGY (2019)
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Christina Claus et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation
Eric Hatterer et al.
MABS (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
Xinyi Guo et al.
NATURE MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Thomas Duhen et al.
NATURE COMMUNICATIONS (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
Jonathan P. O. Hebb et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
David Y. Oh et al.
CANCER RESEARCH (2017)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
Luuk van Hooren et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
Yariv Mazor et al.
SCIENTIFIC REPORTS (2017)
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
M. B. Atkins et al.
ANNALS OF ONCOLOGY (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets
John J. Rhoden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
Songmao Zheng et al.
MABS (2016)
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
Ryan Montler et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2016)
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody
Stephen W. Jarantow et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Improving target cell specificity using a novel monovalent bispecific IgG design
Yariv Mazor et al.
MABS (2015)
Insights into the molecular basis of a bispecific antibody's target selectivity
Yariv Mazor et al.
MABS (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells
Ingo Schubert et al.
MABS (2014)
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies
Brian D. Harms et al.
METHODS (2014)
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
Pia Kvistborg et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
Linda C. Sandin et al.
ONCOIMMUNOLOGY (2014)
Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
Marieke F. Fransen et al.
CLINICAL CANCER RESEARCH (2013)
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Aurelien Marabelle et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation
Omar S. Qureshi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Guidelines for the welfare and use of animals in cancer research
P. Workman et al.
BRITISH JOURNAL OF CANCER (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Structural characterization of a human Fc fragment engineered for lack of effector functions
Vaheh Oganesyan et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2008)
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity
Andrew D. Simmons et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses
Sebastian Tuve et al.
CANCER RESEARCH (2007)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Structural analysis of CTLA-4 function in vivo
EL Masteller et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
